Case C-118/24, Laboratoires Eurogenerics and Theramex France: Judgment of the Court (Second Chamber) of 23 April 2026 (request for a preliminary ruling from the Conseil d’État – France) – EG Labo Laboratoires Eurogenerics SAS, Theramex France SAS v Agence nationale de sécurité du médicament et des produits de santé (ANSM), Biogaran SAS (Reference for a preliminary ruling – Directive 2001/83/EC – Medicinal products for human use – Articles 28 and 29 – Decentralised procedure for marketing authorisation for a medicinal product – Article 10 – Generic medicinal product – Abridged procedure for granting a marketing authorisation – Biological medicinal product serving as reference medicinal product for a chemical medicinal product – Jurisdiction of the courts of the Member States concerned to determine whether there is a potential serious risk for public health – Jurisdiction of those courts to review the conditions for granting a marketing authorisation for a generic medicinal product)